Antibiotics for trachoma

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 9, 2019, Pages

  Evans, Jennifer R ^a   Solomon, Anthony W ^b   Kumar, Rahul ^c   Perez, Ángela ^d   Singh, Balendra P ^c   Srivastava, Rajat Mohan ^c   Harding Esch, Emma ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

^d Institute for Health Technology Assessment   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE; OXYTETRACYCLINE; PLACEBO; SULFONAMIDE; TETRACYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; CHLAMYDIA TRACHOMATIS; DISEASE ELIMINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TRACHOMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; DRUG EFFECT; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; CHLAMYDIA TRACHOMATIS; DRUG RESISTANCE, BACTERIAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRACHOMA; TREATMENT OUTCOME;

EID: 85072791506     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001860.pub4     Document Type: Review

References (179)

1. Schachter J, West SK, Mabey DC, Dawson CR, Bobo L, Bailey R, et al. Azithromycin in control of trachoma. Lance 1999;354(9179):630–5.
2. Schachter J, West SK, Mabey DC, Dawson CR, Bobo L, Bailey R, et al. Azithromycin in control of trachoma. Lance 1999;354(9179):630–5.
3. Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DC. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization 2001;79(7): 632–40.
4. Schachter J, West SK, Mabey DC, Dawson CR, Bobo L, Bailey R, et al. Azithromycin in control of trachoma. Lancet 1999;354(9179):630–5.
5. Atik B, Thanh TT, Luong VQ, Lagree S, Dean D. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 2006;296(12):1488–97.
6. Attiah MA, el Kohly AM. Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma 1973;50(3):11–20.
7. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342(8869):453–6.
8. Bowman RJ, Sillah A, van Debn C, Goode V, Muquit M, Johnson GJ, et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science 2000;41(13): 4074–9.
9. Cochereau I, Goldschmidt P, Goepogui A, Afghani T, Delval L, Pouliquen P, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. British Journal of Ophthalmology 2007;91(5):667–72.
10. Darougar S, Jones BR, Viswalingam N, Poirier RH, Allami J, Houshmand A, et al. Family-based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology 1980;64(4):291–5.
11. Sherman Dawson CR, Hanna L, Wood TR, Coleman V, Briones OC, Jawetz E. Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases 1969;119(6):581–90.
12. Stewart Dawson CR, Hanna L, Wood TR, Coleman V, Briones OC, Jawetz E. Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases 1969;119(6):581–90.
13. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases 1997;24(3):363–8.
14. Foster SO, Powers DK, Thygeson P. Trachoma therapy: a controlled study. American Journal of Ophthalmology 1966; 61(3):451–5.
15. Hoshiwara I, Ostler HB, Hanna L, Cignetti F, Coleman VR, Jawetz E. Doxycycline treatment of chronic trachoma. JAMA 1973;224(2):220–3.
16. NCT00618449. Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/ NCT00618449 (first received 20 February 2008).
17. Peach H, Piper S, Devanesen D, Dixon B, Jeffries C, Braun P, et al. Northern Territory trachoma control and eye health committee’s randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74–6.
18. Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, West SK, et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology 2018;102(5):680–6.
19. Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, Zhou Z, et al. A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases 2017;64(6):743–50.
20. Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, et al. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. PLoS Neglected Tropical Diseases 2012;6(4):e1586.
21. Amza A, Kadri B, Nassirou B, Yu SN, Stoller NE, Bhosai SJ, et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases 2013;7(1):e1983.
22. Amza A, Yu SN, Kadri B, Nassirou B, Stoller NE, Zhou Z, et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial. PLoS Neglected Tropical Diseases 2014;8(9):e3128.
23. Gaynor BD, Amza A, Gebresailassie S, Kadri B, Nassirou B, Stoller NE, et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene 2014;91(3):577–9.
24. Keenan JD, Chin SA, Amza A, Kadri B, Nassirou B, Cevallos V, et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster-randomized trial. Clinical Infectious Diseases 2018;67(11): 1743–9.
25. Liu F, Porco TC, Amza A, Kadri B, Nassirou B, West SK, et al. Short-term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors 2015;8(1):535.
26. Liu F, Porco TC, Amza A, Kadri B, Nassirou B, West SK, et al. Short-term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases 2015;9(8): e0004000.
27. O’Brien KS, Cotter SY, Amza A, Kadri B, Nassirou B, Stoller NE, et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster-randomized trial in Niger. Pediatric Infectious Disease Journal 2018;37(11):1082–6.
28. O’Brien KS, Cotter SY, Amza A, Kadri B, Nassirou B, Stoller NE, et al. Mass azithromycin and malaria parasitemia in Niger: results from a community-randomized trial. American Journal of Tropical Medicine and Hygiene 2017;97 (3):696–701.
29. Oldenburg CE, Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal 2018;37(6):506–10.
30. Oldenburg CE, Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster-randomized trachoma trial. American Journal of Tropical Medicine and Hygiene 2018;98(2):389–95.
31. Stoller NE, Amza A, Boubacar K, Beido N, Yu SN, Keenan JD, et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene 2014;91(5 Suppl 1):323.
32. Yu SN, Amza A, Kadri B, Nassirou B, Zhou Z, Stoller NE, et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret-Niger. American Journal of Tropical Medicine and Hygiene 2014;91:317–8.
33. Tanzania Seidman JC, Coles CL, Silbergeld EK, Levens J, Mkocha H, Johnson LB, et al. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology 2014;43(4):1105–13.
34. Seidman JC, Johnson LB, Levens J, Mkocha H, Munoz B, Silbergeld EK, et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non-pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology 2016;7:1420.
35. Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology 2013;131(4):431–6.
36. Gambia Bojang E, Jafali J, Perreten V, Hart J, Harding-Esch EM, Sillah A, et al. Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology 2017;17:75.
37. Burr SE, Hart J, Edwards T, Harding-Esch EM, Holland MJ, Mabey DC, et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health 2014;14:1176.
38. Burr SE, Hart JD, Edwards T, Baldeh I, Bojang E, Harding-Esch EM, et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases 2013;7(7):e2347.
39. Burr SE, Milne S, Jafali J, Bojang E, Rajasekhar M, Hart J, et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia. Bulletin of the World Health Organization 2014;92(7):490–8.
40. Harding-Esch E, Jofre-Bonet M, Dhanjal JK, Burr S, Edwards T, Holland M, et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases 2015;9(4):e0003670.
41. Harding-Esch EM, Edwards T, Mkocha H, Munoz B, Holland MJ, Burr SE, et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases 2010;4(11):e861.
42. Harding-Esch EM, Sillah A, Edwards T, Burr SE, Hart JD, Joof H, et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases 2013;7(6):e2115.
43. Hart JD, Edwards T, Burr SE, Harding-Esch EM, Takaoka K, Holland MJ, et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health 2014; 19(2):207–11.
44. Resnikoff S, Peyramaure F, Bagayogo CO, Huguet P. Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1995;7289-98:101–10.
45. Shukla BR, Nema HV, Mathur JS, Nath K. Gantrisin and madribon in trachoma. British Journal of Ophthalmology 1966;50(4):218–21.
46. Tabbara KF, Abu el Asrar A, al Omar O, Choudhury AH, al Faisal Z. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996;103(5):842–6.
47. Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 2012;379 (9811):143–51.
48. Gebre T, Ayele B, Zerihun M, House JI, Stoller NE, Zhou Z, et al. Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene 2011;85 (3):518–23.
49. House JI, Ayele B, Porco TC, Zhou Z, Hong KC, Gebre T, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet 2009;373(9669):1111–8.
50. Keenan JD, Ayele B, Gebre T, Moncada J, Stoller NE, Zhou Z, et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases 2012;54(2):253–6.
51. Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases 2011;52(7):883–8.
52. Keenan JD, Sahlu I, McGee L, Cevallos V, Vidal JE, Chochua S, et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society 2016;5(2):222–6.
53. Keenan JD, See CW, Moncada J, Ayele B, Gebre T, Stoller NE, et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science 2012;53(1): 235–40.
54. Keenan JD, Tadesse Z, Gebresillasie S, Shiferaw A, Zerihun M, Emerson PM, et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine 2018;15 (8):e1002633.
55. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009;302(9):962–8.
56. Ray KJ, Zhou Z, Cevallos V, Chin S, Enanoria W, Lui F, et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology 2014;21(2): 86–91.
57. Skalet AH, Cevallos V, Ayele B, Gebre T, Zhou Z, Jorgensen JH, et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Medicine 2010;7 (12):e1000377.
58. TEF Cevallos V, Whitcher JP, Melese M, Alemayehu W, Yi E, Chidambaram JD, et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science 2012;53(9): 5208–12.
59. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 2006;295 (10):1142–6.
60. Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases 2009;3(2):e376.
61. Lee S, Alemayehu W, Melese M, Lakew T, Lee D, Yi E, et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene 2007;76(1):129–31.
62. Melese M, Alemayehu W, Lakew T, Yi E, House J, Chidambaram JD, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008;299(7):778–84.
63. Morberg DP, Alemayehu W, Melese M, Lakew T, Sisay A, Zhou Z, et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology 2019; 26(1):19–26.
64. See CW, Alemayehu W, Melese M, Zhou Z, Porco TC, Shiboski S, et al. How reliable are tests for trachoma?-a latent class approach. Investigative Ophthalmology and Visual Science 2011;52(9):6133–7.
65. Wilson N, Goodhew B, Mkocha H, Joseph K, Bandea C, Black C, et al. Evaluation of a single dose of azithromycin for trachoma in low-prevalence communities. Ophthalmic Epidemiology 2019;26(1):1–6.
66. Woolridge RL, Cheng KH, Chang IH, Yang CY, Hsu TC, Grayston JT. Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology 1967;63 Suppl(5):1577–86.
67. Abdou A, Nassirou B, Kadri B, Moussa F, Munoz BE, Opong E, et al. Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger. British Journal of Ophthalmology 2007;91(1):13–7.
68. Assaad FA, Maxwell Lyons F, Sundaresan T. Report of 4 years’ follow-up of a trachoma clinical trial in Taiwan. Bulletin of the World Health Organization 1968;38(4): 565–76.
69. Astle W, Wiafe B, Ingram A, Mwanga M, Glassco C. Trachoma control in Southern Zambia-an international team project employing the SAFE strategy. Ophthalmic Epidemiology 2006;13(4):227–36.
70. Babbar OP, Chhatwal VK, Ray IB, Mehra MK. Effect of berberine chloride eye drops on clinically positive trachoma patients. Indian Journal of Medical Research 1982;76 Suppl: 83–8.
71. Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, Zhou Z, et al. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. Ophthalmology 2009;116(11):2047–50.
72. Bietti GB. Further contributions on the value of osmotic substances as means to reduce intra-ocular pressure. Transactions of the Ophthalmological Society of Australia 1967;26:61–71.
73. Broman AT, Shum K, Munoz B, Duncan DD, West SK. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Investigative Ophthalmology and Visual Science 2006;47(1):99–104.
74. Cerulli L, Cedrone C, Assefa C, Scuderi GL. Evaluation of treatment against trachoma in two regions of Ethiopia. Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1983:67–83.
75. Chumbley LC, Viswalingam ND, Thomson IM, Zeidan MA. Treatment of trachoma in the West Bank. Eye 1988;2 (Pt 5):471–5.
76. Coulibaly YI, Dicko I, Keita M, Keita MM, Doumbia M, Daou A, et al. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. PLoS Neglected Tropical Diseases 2013;7(5):e2221.
77. Daghfous T, Dawson CR, Messadi M, Hoshiwara I, Vastine D. Comparative study of the effect of rifampicin and tetracycline versus placebo in the treatment of trachoma [Etude comparative de l’action de la rifampicine et de tetracycline et d’un placebo dans le traitement du trachome]. International Review of Trachoma 1974;51:71–80.
78. Daghfous MT, Dawson CR, Kammoun M, Romdhane K, Djerad A. Effect of oral doxycycline and 1% tetracycline ointment in the treatment of severe trachoma [Action de la doxycycline par voie orale et de la tetracycline pommade 1% dans le traitement du trachome severe]. Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1985;62(1-2):47–51.
79. Darougar S, Jones BR, Viswalingam N, Allami J, Minassian D, Farahmandian MA, et al. Topical therapy of hyperendemic trachoma with rifampicin, oxytetracycline, or spiramycin eye ointments. British Journal of Ophthalmology 1980;64(1):37–42.
80. Darougar S, Viswalingam N, El Sheikh H, Hunter PA, Yearsley P. A double-blind comparison of topical therapy of chlamydial ocular infection (TRIC infection) with rifampicin or chlortetracycline. British Journal of Ophthalmology 1981;65(8):549–52.
81. Dawson CR, Hanna L, Jawetz E. Controlled treatment trials of trachoma in American Indian children. Lancet 1967;2(7523):961–4.
82. Dawson CR, Hanna L, Wood TR, Jawetz E. Double-blind treatment trials in chronic trachoma of American Indian children. Antimicrobial Agents and Chemotherapy 1967;7: 137–42.
83. Dawson CR, Elashoff R, Hanna L, Wood R. The evaluation of controlled trachoma chemotherapy trials. International Review of Trachoma 1968;45(1):77–85.
84. Dawson CR, Ostler HB, Hanna L, Hoshiwara I, Jawetz E. Tetracyclines in the treatment of chronic trachoma in American Indians. Journal of Infectious Diseases 1971;124 (3):255–63.
85. Dawson CR, Elashoff R, Hanna L, Wood R. The evaluation of controlled trachoma chimiotherapy trial. International Review of Trachoma 1972;49(1):67–84.
86. Dawson CR, Hanna L. Controlled treatment trials in trachoma: a resume of experience with topical and systemic tetracycline and systemic sulfonamide. International Review of Trachoma 1972;49(1):53–66.
87. Dawson CR, Daghfous T, Messadi M, Hoshiwara I, Vastine DW, Yoneda C, et al. Microbiologic findings in a controlled trial of rifampicin and tetracycline for the treatment of severe endemic trachoma in Tunisia. International Review of Trachoma 1974;51(4):59–69.
88. Dawson CR, Daghfous T, Messadi M, Hoshiwara I, Vastine DW, Yoneda C, et al. Severe endemic trachoma in Tunisia. II. A controlled therapy trial of topically applied chlortetracycline and erythromycin. Archives of Ophthalmology 1974;92(3):198–203.
89. Dawson CR, Hoshiwara I, Daghfous T, Messadi M, Vastine DW, Schachter J. Topical tetracycline and rifampicin therapy of endemic trachoma in Tunisia. American Journal of Ophthalmology 1975;79(5):803–11.
90. Dawson CR, Daghfous T, Whitcher J, Messadi M, Hoshiwara T, Triki F, et al. Intermittent trachoma chemotherapy: a controlled trial of topical tetracycline or erythromycin. Bulletin of the World Health Organization 1981;59(1):91–7.
91. Dawson CR, Daghfous T, Hoshiwara I, Ramdhane K, Kamoun M, Yoneda C, et al. Trachoma therapy with topical tetracycline and oral erythromycin: a comparative trial. Bulletin of the World Health Organization 1982;60(3): 347–55.
92. Edwards T, Cumberland P, Hailu G, Todd J. Impact of health education on active trachoma in hyperendemic rural communities in Ethiopia. Ophthalmology 2006;113(4): 548–55.
93. Gower EW, Solomon AW, Burton MJ, Aguirre A, Munoz B, Bailey R, et al. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment. Investigative Ophthalmology and Visual Science 2006;47(11):4767–71.
94. Gupta UC. Study on the role of sulphamethoxypyridazine (oral) in trachoma control. British Journal of Ophthalmology 1966;50(5):262–7.
95. Gupta UC, Parthasarathy NR, Gupta CK. Study of broad-spectrum antibiotic kajal in mass control of trachoma. American Journal of Ophthalmology 1968;65(5):778–81.
96. Guzey M, Aslan G, Ozardali I, Basar E, Satici A, Karadede S. Three-day course of oral azithromycin vs topical oxytetracycline/polymyxin in treatment of active endemic trachoma. Japanese Journal of Ophthalmology 2000;44(4): 381–6.
97. Hasan MM. New drug for the treatment of trachoma (clinical trial report). Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1976;53(3-4):105–17.
98. Humet RM, Fresnadillo A, Fresnadillo E, Piqueras M, Alegre D. Comparative efficacy of two antibiotics: doxycycline and ioamicine for the treatment of infections caused by Chlamydia trachomatis. The importance of screening in the diagnosis. AnaLisis Clinicos 1989;14: 140–4.
99. Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA, et al. A controlled trial of povodine-Iodine to treat infectious conjunctivitis in children. American Journal of Ophthalmology 2002;134(5):681–8.
100. Ji MS. Evaluation of trachoma treatment by the cytological examination of scrapings. Chung Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology] 1986;22(5):294–6.
101. Kamiya S. Mass treatment of trachoma. American Journal of Ophthalmology 1956;42:269–83.
102. Khandekar R, Mohammed AJ, Al Raisi A, Kurup P, Shah S, Dirir MH, et al. Prevalence and distribution of active trachoma in children of less than five years of age in trachoma endemic regions of Oman in 2005. Ophthalmic Epidemiology 2006;13(3):167–72.
103. Litricin O, Talanyi Feifer L. Mass trachoma treatment in areas with low endemicity. International Review of Trachoma 1968;45(2):143–53.
104. Mesfin MM, De La Camera J, Tareke IG, Amanual G, Araya T, Kedir AM. A community-based trachoma survey: prevalence and risk factors in the Tigray region of northern Ethiopia. Ophthalmic Epidemiology 2006;13(3):173–81.
105. Mohan M, Pant CR, Angra SK, Mahajan VM. Berberine in trachoma (a clinical trial). Indian Journal of Ophthalmology 1982;30(2):69–75.
106. Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. New England Journal of Medicine 2018;378: 1583–92.
107. Nabli B, Daghfous MT. A preliminary study of norfloxacin in the treatment of trachoma [Etude preliminaire de la Norfloxacine dans le traitement du trachome]. Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1988;65(1-2):123–7.
108. Azithromycin in Control of Trachoma II. clinicaltrials.gov/ct2/show/NCT00286026 (first received 2 February 2006).
109. Study of three alternatives for mass treatment in trachoma villages of Tanzania. clinicaltrials.gov/ct2/show/NCT00347607 (first received 4 July 2006).
110. Study of azithromycin to prevent recurrent trichiasis following surgery in Ethiopia (STAR). clinicaltrials.gov/ct2/show/NCT00347776 (first received 4 July 2006).
111. The effect of oral azithromycin in the treatment of chlamydial conjunctivitis. clinicaltrials.gov/ ct2/show/NCT01178762 (first received 10 August 2010).
112. A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial (ASANTE). clinicaltrials.gov/ct2/show/ NCT01767506 (first received 14 January 2013).
113. A trial of seasonal malaria chemoprevention plus azithromycin in African children (SMCAZ). clinicaltrials.gov/ct2/show/results/ NCT02211729 (first received 7 August 2014).
114. Ngondi J, Ole-Sempele F, Onsarigo A, Matende I, Baba S, Reacher M, et al. Blinding trachoma in postconflict southern Sudan. PLoS Medicine 2006;3(12):2424–30.
115. Ngondi J, Onsarigo A, Matthews F, Reacher M, Brayne C, Baba S, et al. Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet 2006;368(9535):589–95.
116. Nisbet IT, Graham DM, Spicer PE, Tibbs GJ. Chlorhexidine as an effective agent against Chlamydia trachomatis in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1979; 16(6):855–7.
117. Obikili AG, Oji EO, Shonekan RO, Otti P. A double-blind comparison of picloxydine dihydrochloride (Vitabact eye drops) and sulfacetamide eye drops in the topical therapy of trachoma. Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1988; 65(3-4):119–32.
118. Putschky N, Pott HG, Kuipers JG, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Annals of the Rheumatic Diseases 2006;65(11):1521–4.
119. Reinhards J. Collective antibiotic treatment of trachoma. Bulletin of the World Health Organization 1959;21:665–702.
120. Resnikoff S, Castan R, Peyramaure F, Bagayogo C, Huguet P. Course of trachoma under treatment with 1% oxytetracycline ophthalmic solution [Evolution du trachome sous traitement par collyre a l’oxytetracycline 1%]. Journal of French Ophthalmology 1994;17(10):591–5.
121. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, et al. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerging Infectious Diseases 2014;20 (6):941–9.
122. Schemann JF, Guinot C, Traore L, Zefack G, Dembele M, Diallo I, et al. Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali. Acta Tropica 2007;101(1): 40–53.
123. Tabbara KF, Summanen P, Taylor PB, Burd EM, al Omar O. Minocycline effects in patients with active trachoma. International Ophthalmology 1988;12(1):59–63.
124. Toufic N. Antitrachoma campaigns of the O.C.C.G.E [Campagnes antitrachomateuses de l’O.C.C.G.E]. International Review of Trachoma 1968;45(3):219–27.
125. Wadia I, Bell WJ, Gaber A. Topical meclocycline in the treatment of trachoma in lower Egypt. Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique 1980;57(4):77–86.
126. Werner GT, Sareen DK. Trachoma in Punjab: a study of the prevalence and of mass treatment. Tropical and Geographical Medicine 1977;29(2):135–40.
127. West SK, Emerson PM, Mkocha H, McHiwa W, Munoz B, Bailey R, et al. Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial. Lancet 2006;368 (9535):596–600.
128. Whitcher JP, Dawson CR, Messadi M, Daghfous T, Abdullah NB, Triki F, et al. Severe endemic trachoma in Tunisia: changes in ocular bacterial pathogens in children treated by the intermittent antibiotic regimen. International Review of Trachoma 1974;51(4):49–58.
129. Zhang H, Kandel RP, Atakari HK, Dean D. Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year. British Journal of Ophthalmology 2006;90 (8):943–8.
130. Last A, Cassama E, Bojang E, Nabicassa M, Burr S, Thompson K, et al. Trachoma elimination in an endemic island setting in West Africa: are two doses of oral azithromycin better than one?. American Journal of Tropical Medicine and Hygiene 2015;93(Suppl 4):403–4.
131. Trachoma Elimination Study by Focused Antibiotic (TESFA). clinicaltrials.gov/ct2/show/ NCT03523156 (first received 14 May 2018).
132. Wondimkun SA, Tadesse Z, Callahan K, Emerson PM, Gebeyehu W, Freeman MC, et al. Sanitation, water and instruction in face-washing for trachoma (SWIFT): the cluster-randomized controlled trial’s protocol and rationale. American Journal of Tropical Medicine and Hygiene 2017;97 (5 Suppl 1):185.
133. Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, Safari S, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 2003;47(9):2765–9.
134. Bloch EM, West SK, Mabula K, Weaver J, Mrango Z, Munoz B, et al. Antibiotic resistance in young children in kilosa district, Tanzania 4 years after mass distribution of azithromycin for trachoma control. American Journal of Tropical Medicine and Hygiene 2017;97(3):815–8.
135. Bobba S, Phelan S, Schierhout G, McManus H, Menzies R, Kaldor J. A systemic review of community level interventions in reducing the prevalence of active trachoma. Clinical and Experimental Ophthalmology 2018;46(Suppl 1): 90.
136. Burton MJ, Mabey DC. The global burden of trachoma: a review. PLoS Neglected Tropical Diseases 2009;3:e460.
137. Burton M, Habtamu E, Ho D, Gower EW. Interventions for trachoma trichiasis. Cochrane Database of Systematic Reviews 2015, Issue 11. DOI: 10.1002/14651858.CD004008.pub2
138. Cromwell EA, Courtright P, King JD, Rotondo LA, Ngondi J, Emerson PM. The excess burden of trachomatous trichiasis in women: a systematic review and meta-analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2009;103(10):985–92.
139. Darougar S, Kinnison JR, Jones BR. Simplified irradiated McCoy cell culture for isolation of Chlamydiae. In: Nichols RL editor(s). Trachoma and Related Disorders caused by Chlamydial Agents. Amsterdam: Excerpta Medica, 1970: 63–70.
140. Dawson CR, Hanna L, Wood TR, Coleman V, Briones OC, Jawetz E. Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. J Infect Dis 1969;119 (6):581–90.
141. Dawson CR, Jones BR, Darougar S. Blinding and non-blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions. Bulletin of the World Health Organization 1975;52(3):279–82.
142. Dawson CR, Jones BR, Tarizzo ML. A Guide to Trachoma Control. Geneva: World Health Organization, 1981.
143. Diab MM, Allen RC, Gawdat TI, Saif AS. Trachoma elimination, approaching 2020. Current Opinion in Ophthalmology 2018;29(5):451–7.
144. Donner A. An empirical study of cluster randomization. International Journal of Epidemiology 1982;11(3):283–6.
145. Ejere H, Alhassan MB, Rabiu M. Face washing promotion for preventing active trachoma. Cochrane Database of Systematic Reviews 2015, Issue 2. DOI: 10.1002/14651858.CD003659.pub2
146. Flaxman SR, Bourne RR, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Global Health 2017;5(12):e1221–34.
147. Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, Elliott J, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clinical Infectious Diseases 2002; 35(4):395–402.
148. Garn JV, Boisson S, Willis R, Bakhtiari A, Al-Khatib T, Amer K, et al. Sanitation and water supply coverage thresholds associated with active trachoma: modeling cross-sectional data from 13 countries. PLoS Neglected Tropical Diseases 2018;12:e0006110.
149. Gaynor BD, Holbrook KA, Whitcher JP, Holm SO, Jha HC, Chaudhary JS, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. British Journal of Ophthalmology 2003;87(2):147–8.
150. Gaynor BD, Chidambaram JD, Cevallos V, Miao Y, Miller K, Jha HC, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. British Journal of Ophthalmology 2005;89(9):1097–9.
151. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006; 94(2):130–6.
152. Grassly NC, Ward ME, Ferris S, Mabey DC, Bailey RL. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Neglected Tropical Diseases 2008;2:e341.
153. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
154. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/ handbook.
155. Hong KC, Schachter J, Moncada J, Zhou Z, House J, Lietman TM. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerging Infectious Diseases 2009;15(7): 1088–90.
156. Katz J, Zeger SL, Tielsch JM. Village and household clustering of xerophthalmia and trachoma. International Journal of Epidemiology 1988;17(4):865–9.
157. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clinical Infectious Diseases 1997;24(3):356–62.
158. MacCallan AF. Trachoma. London: Butterworth, 1936.
159. O’Brien KS, Emerson P, Hooper PJ, Reingold AL, Dennis EG, Keenan JD, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infectious Diseases 2019;19(1):e14–25.
160. Rabiu M, Alhassan MB, Ejere HOD, Evans JR. Environmental sanitary interventions for preventing active trachoma. Cochrane Database of Systematic Reviews 2012, Issue 2. DOI: 10.1002/14651858.CD004003.pub3
161. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
162. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
163. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
164. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Mabey DC, et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy 2005;49(11):4804–6.
165. Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DC, Foster A. Trachoma Control: a Guide for Programme Managers. Geneva: World Health Organization, 2006.
166. Sutter EE, Ballard RC. Community participation in the control of trachoma in Gazankulu. Social Science and Medicine 1983;17(22):1813–7.
167. Thygeson P. Trachoma Manual and Atlas. Vol. No 41, Public Health Service Publication, 1960.
168. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bulletin of the World Health Organization 1987;65(4):477–83.
169. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2018. WHO-Weekly Epidemiological Record 2019;94(29):317-28. [www.who.int/wer/2018/wer9429/en/]
170. West SK, Munoz B, Turner VM, Mmbaga BB, Taylor HR. The epidemiology of trachoma in central Tanzania. International Journal of Epidemiology 1991;20(4):1088–92.
171. West SK, Moncada J, Munoz B, Mkocha H, Storey P, Hardick J, et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?. Journal of Infectious Diseases 2014;210(1):65–71.
172. World Health Assembly. WHA51.11 Global elimination of blinding trachoma. www.who.int/blindness/causes/ WHA51.11/en/ (accessed 22 November 2018).
173. World Health Organization. Criteria of clinical diagnosis. Expert Committee in Trachoma. 1962; Vol. Third report:8.
174. World Health Organization. Report of the 3rd global scientific meeting on trachoma. www.who.int/trachoma/ resources/who pbd 2.10/en/.
175. World Health Organization. World Health Organization Strategic and Technical Advisory Group on Neglected Tropical Diseases. Monitoring and Evaluation Working Group Sub-Group 2. Technical Consultation on Trachoma Surveillance; 2014 September 11−12, 2014 Task Force for Global Health; Decatur (GA). 2014.
176. World Health Organization. Trachoma. www.who.int/ trachoma/disease/en/ (accessed 20 November 2018).
177. Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database of Systematic Reviews 2011, Issue 3. DOI: 10.1002/14651858.CD001860.pub3
178. Mabey D, Fraser-Hurt N. Antibiotics for trachoma. Cochrane Database of Systematic Reviews 2002, Issue 1. DOI: 10.1002/14651858.CD001860.pub2
179. Mabey D, Fraser-Hurt N, Powell C. Antibiotics for trachoma. Cochrane Database of Systematic Reviews 2005, Issue 2. DOI: 10.1002/14651858.CD001860.pub2